Recent data have suggested that regular consumption of nonsteroid anti-inflammatory drugs (NSAIDs), particularly selective inhibitors of cyclooxygenase-2 (COX-2), is associated with an increased risk of thrombotic events. It has been suggested that this is due to NSAIDs reducing the release from the endothelium of the antithrombotic mediator prostaglandin I 2 as a result of inhibition of endothelial COX-2. Here, however, we show that despite normal human vessels and endothelial cells containing cyclooxygenase-1 (COX-1) without any detectable COX-2, COX-1 in vessels or endothelial cells is more readily inhibited by NSAIDs and COX-2-selective drugs than COX-1 in platelets (e.g., log IC 50 ؎SEM values for endothelial cells vs. platelets: naproxen -5.59؎0.07 vs. 
Nonsteroid anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, naproxen, and rofecoxib have, in one form or another, been used for many thousands of years for the relief of inflammation and pain. However, NSAIDs can also produce a number of well-characterized side effects. In particular, their use is linked to an increased risk of gastrointestinal adverse events, the most serious being obstructions, perforations, ulcers, and bleeds (1) . In the U.S. the annual death rate from NSAID-induced gastrointestinal bleeds is estimated to be 0.08% (2) . NSAIDs owe their therapeutic benefits, as well as their side effects, to inhibition of the enzyme cyclo-oxygenase (COX; refs. 3, 4) . COX exists in two isoforms: COX-1 and COX-2. In general terms, COX-1 is the constitutive isoform present in many tissues associated with the production of prostanoids for physiological functions, whereas COX-2 is the inducible isoform that appears at sites of inflammation and is associated with the production of prostanoids involved in inflammatory responses. In the last decade or so COX-2-selective drugs such as celecoxib, rofecoxib, and lumiracoxib have been produced with the aim of targeting COX-2 in inflammatory sites while leaving COX-1 largely unaffected. This is consistent with the idea that inhibition of COX-1 underlies the gastrointestinal side effects of NSAIDs and that NSAID drug selectivity toward inhibition of COX-1 over COX-2 correlates with their ability to cause gastrointestinal side effects (5) . Indeed, in controlled clinical trials selective inhibitors of COX-2, including lumiracoxib and rofecoxib, produce fewer severe gastrointestinal adverse events than traditional (nonselective) NSAIDs (3, 4) .
COX products are important to the normal functioning of the cardiovascular system, particularly prostaglandin (PG) I 2 produced by endothelial cells and thromboxane (Tx) A 2 formed by platelets (3, 4) . PGI 2 is antithrombotic and vasodilating; it also reduces vascular remodeling and limits cholesterol uptake (6, 7) . In contrast, TxA 2 is prothrombotic and vasoconstricting, and promotes vascular remodeling (6, 7) . Drugs that inhibit TxA 2 production therefore reduce platelet reactivity whereas drugs that inhibit PGI 2 production increase it. In clinical use, low-dose aspirin works by inhibiting COX in platelets and reducing TxA 2 production while having relatively less effect on PGI 2 production. This profile of activity is associated with an increase in bleeding time and a reduction in the risk of heart attack and stroke (8 -10) . In contrast, in humans COX-2-selective drugs reduce whole-body production of PGI 2 while leaving TxA 2 much less affected (11, 12) . Because of this ability to reduce whole-body production of antithrombotic PGI 2 , supported by observations that COX-2 knockout mice have greatly reduced levels of urinary PGI 2 metabolite (13), it has been suggested that the COX-2-selective drugs could increase the risk of thrombotic events. This hypothesis is supported particularly by the increased rate of thrombotic events recorded in placebo-controlled trials of COX-2-selective inhibitors (14, 15) .
The mechanisms underlying the inhibition of PGI 2 production by COX-2-selective drugs have not actually been directly identified, as it has been assumed that this effect alone demonstrates the predominance of COX-2 in endothelial cells. However, with the notable exception of the kidneys and sometimes lungs, COX-2 expression is rarely detected in either large conduit vessels or microvessels such as those in the brain, breast, gut, joint, liver, mouth, prostate, or skin in the absence of local inflammation or disease (4, 16 -26) . Furthermore, observational studies suggest that similar to COX-2-selective drugs, traditional NSAIDs such as ibuprofen and diclofenac may also increase the risk of cardiovascular events (4, (27) (28) (29) (30) . We hypothesized, therefore, that rather than differences in COX isoform, it could be differences in intracellular conditions, such as the relative levels of lipid peroxides, that are at a much higher level in platelets than in the endothelium (31, 32) , or the supply of arachidonic acid substrate (33, 34) that influenced NSAID potencies.
In the current study we used human blood vessels, human endothelial cells, and human platelets and have taken a classical pharmacological approach to show that despite endothelial cells containing COX-1, their production of PGI 2 is inhibited by both COX-2-selective inhibitors and traditional NSAIDs more strongly than the production of TxA 2 by platelets. We suggest that by examining COX activity in endothelial cells, platelets, and cells expressing COX-2, it will be possible to identify drugs with the desired anti-inflammatory and analgesic properties of traditional NSAIDs but without the accompanying risk of gastrointestinal and cardiovascular side effects.
MATERIALS AND METHODS

COX activity in combination assay of human endothelial cells and platelets
Primary cultures of human aortic endothelial cells were cultured in 96-well plates for COX activity experiments and in 6-well plates for the generation of samples for Western blot. For COX activity assays, freshly taken human whole blood, platelet-rich plasma (PRP; prepared by centrifugation of whole blood, 200 g, at room temperature for 7 min), aspirintreated (10 Ϫ4 M, 6 h), whole blood, or culture medium was added to the endothelial cells. In some experiments whole blood was added to empty 96-well plates. Test agents (all 10 Ϫ10 to 10 Ϫ3 M) or vehicle (0.1% v/v dimethyl sulfoxide) were then added and the plates were incubated for 60 min, followed by addition of the calcium ionophore, A23187 (5ϫ10 Ϫ5 M). After a further 30 min incubation period, samples were centrifuged (1500 g, 4°C, 5 min) and the incubation medium was removed and immediately frozen. Concentrations of 6-keto-PGF 1␣ (as a measure of PGI 2 formation within the endothelial cells) and TxB 2 (as a measure of TxA 2 formation by platelets) in samples were then determined by RIA.
COX activity in homogenates of human endothelial cells and human platelets
One T75 flask each of confluent cultures of human aortic endothelial cells was washed with PBS, then scraped into ice-cold assay buffer (PBS containing EGTA, 10 Ϫ3 M, and phenylmethysulfonylfluoride, 10 Ϫ3 M). Cells were then homogenized with 10 strokes in a glass Teflon TM homogenizer in 7 ml of assay medium. To prepare platelet homogenates, 50 ml of human whole blood was collected into trisodium citrate (3.15% w/v) and centrifuged (200 g, room temperature, 7 min). The platelet supernatant was then removed, treated with 300 ng/ml PGI 2 , and centrifuged (1000 g, 15 min, room temperature). The platelet pellet was resuspended in 7 ml of assay buffer and homogenized as for endothelial cells; 100 l of homogenate was then added to individual wells of a 96-well plate together with 5 ϫ 10 Ϫ3 M of epinephrine and test agents (all 10 Ϫ10 to 10 Ϫ3 M) or vehicle (0.1% v/v dimethyl sulfoxide). Plates were then incubated for 1 h before addition of 3 ϫ 10 Ϫ5 M arachidonic acid and incubation for another 15 min. Diclofenac 10 Ϫ3 M was then added and the samples centrifuged (1500 g, 4°C, 5 min); the incubation medium was removed and immediately frozen. Concentrations of PGE 2 and 6-keto-PGF 1␣ (as a measure of PGI 2 formation within the endothelial cells) or TxB 2 (as a measure of TxA 2 formation by platelets) in samples were then determined by RIA.
COX activity in whole human vessels
Human saphenous vein was obtained during coronary artery bypass surgery. Informed consent was obtained from patients under the approval of the Royal Brompton Hospital Research Ethics Committee. Vessels were cleared of connective tissue and dissected into sections ϳ 5 mm wide. Care was taken to preserve endothelial integrity. Segments of vessel were incubated for 60 min in plasma derived from the patient's blood in the presence of either aspirin (10 Ϫ4 M), ibuprofen (1.5ϫ10 Ϫ4 M), rofecoxib (3ϫ10 Ϫ6 M), or vehicle. After 60 min COX activity was stimulated by the addition of arachi-donic acid (3ϫ10 Ϫ5 M) and incubation for another 30 min. Plasma was removed from the incubates and production of PGI 2 was determined by RIA as above. To control for the carryover of prostanoids from tissue preparation, some incubates were made in the presence of diclofenac 10 Ϫ3 M. Vessels demonstrating high levels of immunoreactive 6-keto-PGF 1␣ under such conditions were excluded from further analyses.
Effect of hydroperoxides on NSAID inhibition of endothelial cell PGI 2 production
To test the effects of hydroperoxides on the potencies of NSAIDs against endothelial cell PGI 2 production, primary human endothelial cells were cultured in 96-well plates. Once confluent, medium was replaced with fresh medium with the addition of test drugs, acetaminophen (10
, or vehicle together with the cell-permeable organic hydroperoxide, t-butylOOH (10 Ϫ4 M), for 60 min. Calcium ionophore (A23187, 5ϫ10 Ϫ5 M) was then added and incubation continued for 30 min, then the reaction was stopped by the addition of diclofenac (10 Ϫ3 M). Conditioned medium was removed to measure 6-keto-PGF 1␣ as above.
Western blot analysis for cyclo-oxygenase-1 and cyclooxygenase-2
Western blot analysis was performed as described previously (32) . Cells were either left untreated or incubated for 24 h with interleukin (IL)-1␤ (1 ng ml Ϫ1 ) to induce COX-2 protein expression in 6-well culture plates. Cells were washed twice with cold PBS before protein was extracted into buffer (Tris 5ϫ10 Ϫ3 M, ethylenediaminetetraacetic acid 10 Ϫ2 M, Triton X-100 1% v/v, phenylmethylsulfonyl fluoride 10 Ϫ3 M). The resulting cell extract was boiled with gel loading buffer containing 2 mg ml Ϫ1 bromphenol blue in a ratio of 1:1. Approximately 20 g of protein as determined by Bradford protein assay was loaded onto a 7.5% SDS separating gel. After electrophoretic separation (1 h at 100 V; Bio-Rad, Hercules, CA, USA), samples were transferred to nitrocellulose (1 h at 100 V) and probed with a specific COX-1 or COX-2 antibody (Ab) raised in rabbit. The blot was then incubated with anti-rabbit immunoglobulin (Ig) E (raised in goat) linked to horseradish peroxidase and visualized using enhanced chemiluminescence (Amersham, Bucks, U.K.).
Materials
Human aortic endothelial cells were purchased from TCS CellWorks Ltd. (Bucks, UK). Arachidonic acid sodium salt, calcium ionophore (A23187), epinephrine, ibuprofen, indomethacin, and naproxen were from Sigma Chemical Co. (Poole, Dorset, UK) as were antibodies to 6-ketoPGF 1␣ , TxB 2 (stable breakdown products of PGI 2 and TxA 2 , respectively) and PGE 2 . Antibodies to COX-1 and COX-2 were purchased from Cayman Chemicals (Ann Arbor, MI, USA 
RESULTS
COX expression in human aortic endothelial cells
Western blot analysis demonstrated that primary cultures of human aortic endothelial cells contained COX-1, with no detectable expression of COX-2 ( Fig.  1) Ϫ1 when incubated with blood, and 8.62 Ϯ 0.76 ng ml Ϫ1 when incubated with PRP (nϭ21). As PRP had an equally neutral effect as blood on endothelial production of 6-keto-PGF 1␣ and since neutrophils within whole blood can produce PGI 2 and influence platelet activity (35; unpublished observations), additional studies were conducted using a combination of endothelial cells and PRP. In these combination assays, addition of aspirin, celecoxib, ibuprofen, naproxen, or rofecoxib caused concentration-dependent reductions in the production of 6-keto-PGF 1␣ and TxB 2 ( Fig. 2; Table 1) . All compounds tested inhibited production of 6-keto-PGF 1␣ more potently than the production of TxB 2 , particularly celecoxib and rofecoxib. The rank ordering of potency of the drugs tested on COX-1 in the platelet was aspirin Ͼ naproxen Ͼ ibuprofen Ͼ rofecoxib ϭ celecoxib; the rank ordering of potency of the drugs on COX-1 in endothelial cells was aspirin Ͼ celecoxib ϭ i1, i2, i3) . ibuprofen ϭ naproxen Ͼ rofecoxib (Fig. 2, Table 1 ). The rank order of potencies previously demonstrated for these compounds against COX-2 within IL-1␤-treated A549 cells is rofecoxib ϭ celecoxib Ͼ aspirin Ͼ ibuprofen Ͼ naproxen (IC 50 values respectively 0.31, 0.34, 2.13, 19.56, and 35.26ϫ10 Ϫ6 M; Fig. 2 ).
Effects of NSAIDs on production of PGI 2 and TxA 2 in homogenates of endothelial cells and platelets
Similar to observations made with intact cells, each NSAID tested caused concentration-dependent inhibitions of COX activity in the homogenate preparations. The differences in potency of the NSAIDs between COX-1 in endothelial cells and COX-1 in platelets was lost following homogenization (Fig. 3) .
Characterization of cyclo-oxygenase in human blood vessels
We confirmed our observations from studies with endothelial cells using intact human blood vessels. Western blot analysis demonstrated that human internal mammary artery, saphenous vein, or radial artery contained detectable levels of COX-1 but not COX-2 (Fig.  4A) . While human blood vessels did not contain any detectable COX-2, the basal production of PGI 2 by vessel segments incubated in plasma (3.46Ϯ1.42 ng 6-keto-PGF 1␣ , nϭ13) was inhibited by Ն 50% in the presence of aspirin (10
Effect of hydroperoxides on NSAID inhibition of endothelial cell PGI 2 production
Addition of t-butylOOH to endothelial cell incubates for 60 min reduced the inhibition of 6-keto-PGF 1␣ production caused by acetaminophen (10 Ϫ4 M) or rofecoxib (3ϫ10 Ϫ6 M) but did not affect the inhibition caused by aspirin (10 Ϫ4 M) or ibuprofen (10 Ϫ4 M) (Fig. 5) .
DISCUSSION
The potential of NSAIDs, including COX-2 selective drugs, to increase the risk of heart attack and stroke has become a recent worldwide concern (3, 4). Indeed, this risk is now receiving more attention than the wellcharacterized ability of NSAIDs to precipitate gastric ulcers and other gastrointestinal adverse events. When selective inhibitors of COX-2 were developed, their potential to cause cardiovascular side effects was not considered; the main objective was to produce drugs that retained the anti-inflammatory and analgesic effects of traditional NSAIDs without their gastrointestinal side effects. Newer drugs such as rofecoxib were therefore tested in animal and human tests of NSAID efficacy and NSAID-induced gastrointestinal damage, but were not examined in models of cardiovascular safety (3, 4, 36, 37) . However, the latest available findings indicate that we must now extend our range of concerns about NSAID toxicity and include cardiovascular risk as an element in the development of new drugs.
In the current study we have modeled in vitro the local environment of blood and blood vessel in vivo. With the exception of studies examining the effects of t-butylOOH, we have used human plasma as an incubation medium to take account of the influences of blood proteins on NSAID potency (38) . We have established in our primary endothelial cells or in human vessels removed surgically and immediately snap-frozen that COX-1 is the predominant isoform present. Indeed, we could not detect the presence of COX-2 protein in any of our cell or tissue samples in the absence of exogenously applied proinflammatory stimuli. Despite the absence of detectable COX-2 in our endothelial cells, we found that selective inhibitors of COX-2 and traditional NSAIDs reduced their production of PGI 2 more potently than platelet production of TxA 2 occurring at the same time in the same incubate. Modeling plasma concentrations resulting from administration of standard doses of the five test drugs in humans (39 -43) into our system suggested a general level of inhibition of PGI 2 production (67Ϯ12%, nϭ5) that accords well with those reported from in vivo studies (3, 4) . Similar modeling shows that at standard dosing, the calculated inhibition of TxA 2 production varies from Ͼ75% for ibuprofen and naproxen to Ͻ10% for celecoxib and rofecoxib. It is important to reinforce the observation that although all the drugs tested inhibited endothelial PGI 2 production much more actively than platelet TxA 2 production selectivity, this could not be accounted for by endothelial cell expression of COX-2, as none was detected by Western blot analysis. Furthermore, as discussed below, the selectivity of drugs for endothelial cell COX-1 is lost when "local environment " is removed by homogenization. Finally, if endothelial cell PGI 2 production was underpinned by the activity of COX-2, this would have been matched by the pharmacological selectivity of the compounds used (i.e., neither the individual potencies of the compounds nor the relative potencies accord with COX-2 underlying the PGI 2 production we detected). This is a key point as it indicates that drugs could be developed that are selective for COX-2 at the site of inflammation without affecting COX-1 in the endothelium.
It has been proposed that endothelial cells in culture, as used in this study, lack COX-2 because they are not exposed to the mechanical forces such as shear that are constantly present within the blood vessel lumen. However, shear of endothelial cells in vitro causes complex changes, including both increases and decreases, in the expressions of COX-1 and COX-2 (4, 5, 44) ; the COX-1 gene even contains the sequence of shear stress-responsive elements within its promoter region (45) . In fact, the constant shear to which endothelial cells within the body are constantly exposed promotes a reduction in proliferation and metabolic rate that is consistent with a resting phenotype. Furthermore, exposure of endothelial cells in vitro to shear for 7 days is not associated with any increase in COX-1 or COX-2 gene transcription (46) . As outlined above, immunohistochemistry provides little evidence for COX-2 expression within the majority of healthy blood vessels. To extend our studies using primary human endothelial cells in culture, we used healthy human blood vessels to more closely model the in vivo production of PGI 2 by the circulatory system. We found that in these vessels, as in the primary cultured endothelial cells, both traditional NSAIDs and COX-2-selective compounds inhibited the production of 6-keto-PGF 1␣ despite the absence of detectable COX-2 protein. Notably, in COX-1 knockout mice, celecoxib fails to increase blood pressure as it does in wild-types (13) . Increases in blood pressure caused by COX-2-selective drugs and traditional NSAIDs could be a causative factor underlying increases in thrombotic events (47) , and it would be intriguing if these are linked to inhibition of COX-1 rather than COX-2.
It is interesting that we found aspirin to be more active on endothelial than platelet COX-1 since, as determined by urinary measurements, aspirin affects whole-body TXA 2 production more strongly than PGI 2 (8) . However, the effects of aspirin on different parts of the circulation are strongly influenced by its pharmacokinetics (i.e., aspirin's short circulating half-life), and these are important contributors to its platelet selectivity (48) . Furthermore, others have reported during skin bleeding that local vascular productions of PGI 2 and TXA 2 are equally sensitive to inhibition by low-dose aspirin (49) . Taking account of aspirin's instability, this could indicate selectivity toward the vascular wall.
The reason why COX-1 in endothelial cells is more sensitive to inhibition by some NSAIDs than COX-1 within the platelet is not clear and is largely beyond the scope of this current study. However, it may well be that the differences in intracellular environment and substrate supply between the endothelium and the platelet dictate the different potencies of these drugs. This would explain the loss in endothelial cell selectivity found in our experiments using broken cell preparations. When endothelial cells and platelets are treated together with NSAIDs (as would be the case in vivo), the production of PGI 2 is inhibited more strongly that that of TxA 2 . One potential intracellular factor of importance is the relative levels of lipid peroxides in platelets vs. the endothelium. We know from studies using acetaminophen that platelets have a much higher level of lipid peroxides than the endothelium (31, 32) . Furthermore, we recently showed that the potencies of other NSAIDs, including rofecoxib, are also reduced when the platelet environment is modeled by increased endogenous lipid peroxides in cells expressing COX-2 (32) . To test this possibility in our endothelial cells, we examined the effects of the cell-permeable organic hydroperoxide, t-butylOOH against the effects of aspirin (an irreversible COX inhibitor), ibuprofen (a traditional NSAID), rofecoxib (a COX-2-selective NSAID), and acetaminophen (as a positive control; ref. 31) . These experiments demonstrated that in our COX-1-containing endothelial cells the inhibitory effects of rofecoxib, but not aspirin or ibuprofen, were significantly reduced when endogenous lipid peroxide levels were elevated. Thus, the large disparity in endogenous lipid peroxide levels in endothelial cells vs. platelets could explain endothelial selectivity for some of the NSAIDs tested, and why these compounds and acetaminophen have strong inhibitory effects on the production of PGI 2 but not TxA 2 in vivo (11, 12, 50) . Intracellular levels of the COX substrate arachidonic acid may also influence the potencies of NSAIDs as many act against COX-2 as simple, competitive substrate inhibitors (33) . Indeed, in low substrate conditions even highly selective COX-2 inhibitors can inhibit the activity of COX-1 (34) . It may well be, therefore, that despite their experimental attractiveness, platelets are poor representatives of COX-1 activity within the body. Activated platelets make large amounts of TxA 2 in a dramatic burst, with accompanying high levels of substrate and high levels of lipid peroxides. PGI 2 and other COX-1 products are more often produced tonically with lower accompanying substrate and lipid peroxide levels. This suggests we must be cautious in attributing differences in NSAID potency against PGI 2 and TxA 2 production in vivo to drug selectivity when enzyme environment can vary so profoundly.
In summary, we show that despite expressing COX-1 in a similar manner without detectable COX-2, endothelial cells and platelets are differentially sensitive to the inhibitory effects of a number of NSAIDs such that endothelial cell production of PGI 2 is inhibited more actively than platelet production of TxA 2 . This observation can offer an explanation as to why NSAIDs, including rofecoxib and celecoxib, might promote a prothrombotic environment. Finally, systems such as those described could assist in the development of NSAIDs that spare both the stomach and the endothelium.
